Table 2.

Clinical responses and characterization of patient PBMC approximately 1 month following adoptive transfer

PatientResponseCD8+/CD4+ T cells per mLTetramer + CD8+/CD4+ T cells (% of CD3+)Tumor-reactive ELISPOTS 105 PBMCaPeptide-specific ELISPOTS 105 PBMC
Synovial cell sarcoma
 1bPR (10)264/1527/23271,980
 2PR (18)327/1942/18455,015
 3PR (3)1,387/24038/41,0754,215
 4NR739/1464/3211,491
 5PR (8)729/1405/1025
 6NR62/166<1/<105
 7PR (47+)144/6512/33753,125
 8PR (11)709/28723/111151,315
 9PR (3)194/12611/2085810
 10PR (5)947/1244/550
 11PR (7)772/24534/238010,305
 13NR344/125NA
 14NR2,311/34612/60825
 15CR (20+)1,712/27126/1474014,280
 16NR600/15120/91203,620
 17PR (4)359/1329/7035
 18NR143/152NA
Melanoma
 19PR (8)1,462/21819/3151,650
 20NR3,095/1,75028/201252,625
 21NR1,774/361<1/<10110
 22CR (24)1,104/1083/<104
 23CR (58+)921/1438/<181,835
 24PR (3)2,693/153<1/<1619
 25NR342/11813/2451,065
 26NR1,543/4257/64011,183
 27NR371/13416/13312880
 28NR221/741/<1040
 29CR (54+)1,002/2578/225620
 30NR108/388/1079673
 31PR (10)265/5105/32601,018
 32NR347/1134/18802,480
 33NR666/19714/178508,223
 34CR (40+)581/12618/83,0259,937
 35PR (28)330/1323/177906
 36PR (5)1,483/3624/94695,110
 37PR (6+)616/61816/4925718,472
 38PR (3)1,462/19372/613430

Abbreviation: NA, sample not available.

  • aTumor-reactive ELISPOT responses were evaluated by stimulating with the HLA-A*02:01+ and NY-ESO-1+ melanoma cell line 624, and peptide-specific ELISPOT responses evaluated by stimulating with an HLA-A*02:01+ EBV-transformed lymphoblastoid cell line that was pulsed with the NY-ESO-1 peptide.

  • bPatients 7, 8, and 9, and 30–34 (first treatment), as well as patients 5, 6, 24, and 27 (second treatment), were immunized with a recombinant AVIPOX virus encoding the NY-ESO-1 HLA-A*0201 T-cell epitope. Patients 1, 3, and 8 received a second infusion, and patient 2 received two additional infusions of TCR-transduced T cells but were not immunized with the recombinant AVIPOX virus. With the exception of patient 2, no patient responded to subsequent treatments with TCR-transduced T cells.